Tag: Phaxiam
PHAXIAM Therapeutics announces the recruitment of the first patient in the phase 1 study in infective endocarditis caused by Staphylococcus aureus – 04/15/2024 at 07:30
The study plans the inclusion of 12 patients in 5 French clinical centers The first results are expected in the 3rd quarter of 2024 This study makes it possible to…
PHAXIAM Therapeutics announces the recruitment of the first patient in the phase 1 study in infective endocarditis caused by Staphylococcus aureus – 04/15/2024 at 07:30
The study plans the inclusion of 12 patients in 5 French clinical centers The first results are expected on 3 th quarter 2024 This study makes it possible to evaluate…
PHAXIAM Therapeutics announces the filing of its 2023 Universal Registration Document (URD) - 04/05/2024 at 6:00 p.m.
Lyon (France) and Cambridge (MA, US), April 5, 2024 – 6:00 p.m. CEST – PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135) biopharmaceutical company developing innovative treatments against severe and resistant bacterial infections…
Phaxiam Therapeutics: an analyst adjusts the cursor
By Hector Chaunu Published on 04/03/2024 at 10:49 a.m. Photo credit © CrostaPics (Boursier.com) — Phaxiam Therapeutics…
PHAXIAM Therapeutics announces the completion of the voluntary withdrawal of its “American Depository Shares” from the Nasdaq Stock Market – 03/11/2024 at 07:00
Lyon (France) and Cambridge (MA, US), March 11, 2024, at 7:00 a.m. CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments against resistant bacterial infections,…
PHAXIAM Therapeutics announces the completion of the voluntary withdrawal of its “American Depository Shares” from the Nasdaq Stock Market – 03/11/2024 at 07:00
Lyon (France) and Cambridge (MA, US), March 11, 2024, at 7:00 a.m. CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments against resistant bacterial infections,…
Phaxiam Therapeutics withdraws from Nasdaq – 02/21/2024 at 10:02
(AOF) – Phaxiam Therapeutics announced that it has officially notified Nasdaq of its intention to voluntarily delist its American Depositary Shares (“ADS”) representing its ordinary shares. The withdrawal should be…
PHAXIAM Therapeutics announces its cash level at the end of 2023 and its 2024 financial calendar – 01/18/2024 at 10:05 p.m.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected] Lyon (France) and Cambridge (MA,…
PHAXIAM Therapeutics provides an update on its activities and publishes its third quarter 2023 results – 11/14/2023 at 10:05 p.m.
Webinar in French on Wednesday November 15, 2023 at 11:00 a.m. CET Pursuit of an ambitious clinical development strategy to create a world leader in phage therapy targeting high value-added…
2023 – PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infectious endocarditis caused by Staphylococcus aureus
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned during the 4th…
PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infective endocarditis caused by Staphylococcus aureus – 10/24/2023 at 10:05 p.m.
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned during the 4th…
PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infective endocarditis caused by Staphylococcus aureus – 10/24/2023 at 10:05 p.m.
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned for the 4th…